Myriad Genetics, Inc [NASDAQ: MYGN] closed the trading session at $5.67 on 2025-08-06. The day’s price range saw the stock hit a low of $4.99, while the highest price level was $5.75.
The stocks have a year to date performance of -78.72 percent and weekly performance of 40.00 percent. The stock has been moved at -54.31 percent over the last six months. The stock has performed 2.16 percent around the most recent 30 days and changed -22.01 percent over the most recent 3-months.
If compared to the average trading volume of 2.13M shares, MYGN reached to a volume of 15556012 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Myriad Genetics, Inc [MYGN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MYGN shares is $7.15 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MYGN stock is a recommendation set at 3.12. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Scotiabank have made an estimate for Myriad Genetics, Inc shares, keeping their opinion on the stock as Sector Perform, with their previous recommendation back on May 21, 2025. The new note on the price target was released on May 08, 2025, representing the official price target for Myriad Genetics, Inc stock. Previously, the target price had yet another raise to $6, while Wells Fargo analysts kept a Equal Weight rating on MYGN stock.
The Price to Book ratio for the last quarter was 1.36, with the Price to Cash per share for the same quarter was set at 0.81.
MYGN stock trade performance evaluation
Myriad Genetics, Inc [MYGN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 40.00. With this latest performance, MYGN shares gained by 2.16% in over the last four-week period, additionally sinking by -54.31% over the last 6 months – not to mention a drop of -58.64% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MYGN stock in for the last two-week period is set at 64.63, with the RSI for the last a single of trading hit 0.42, and the three-weeks RSI is set at 0.36 for Myriad Genetics, Inc [MYGN]. The present Moving Average for the last 50 days of trading for this stock 4.87, while it was recorded at 4.25 for the last single week of trading, and 10.45 for the last 200 days.
Myriad Genetics, Inc [MYGN]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Myriad Genetics, Inc [MYGN] shares currently have an operating margin of -9.21% and a Gross Margin at 68.05%. Myriad Genetics, Inc’s Net Margin is presently recorded at -47.45%.
Myriad Genetics, Inc (MYGN) Capital Structure & Debt Analysis
According to recent financial data for Myriad Genetics, Inc. ( MYGN), the Return on Equity (ROE) stands at -70.03%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -44.85%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Myriad Genetics, Inc’s Return on Invested Capital (ROIC) is -83.32%, showcasing its effectiveness in deploying capital for earnings.
Myriad Genetics, Inc (MYGN) Efficiency & Liquidity Metrics
Based on Myriad Genetics, Inc’s (MYGN) latest financial statements, the Debt-to-Equity Ratio is 0.40%, indicating its reliance on debt financing relative to shareholder equity.
Myriad Genetics, Inc (MYGN) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Myriad Genetics, Inc. (MYGN) effectively leverages its workforce, generating an average of -$146370.37 per employee. The company’s liquidity position is robust, with a Current Ratio of 1.42% and a Quick Ratio of 1.28%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Myriad Genetics, Inc [MYGN] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MYGN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Myriad Genetics, Inc go to 16.06%.
Myriad Genetics, Inc [MYGN]: Institutional Ownership
There are presently around $104.72%, or 107.70%% of MYGN stock, in the hands of institutional investors. The top three institutional holders of MYGN stocks are: BLACKROCK INC. with ownership of 15.15 million shares, which is approximately 16.7227%. VANGUARD GROUP INC, holding 10.06 million shares of the stock with an approximate value of $$246.18 million in MYGN stocks shares; and VANGUARD GROUP INC, currently with $$202.1 million in MYGN stock with ownership which is approximately 9.1197%.
